Treatment of Neuroleptic Induced Acute Akathisia With Trazodone
Information source: BeerYaakov Mental Health Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: Placebo (Drug); Trazodone (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: BeerYaakov Mental Health Center
Summary
Administration of trazodone for the treatment of neuroleptic induced acute akathisia in a
cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Barnes Akathisia rating scale, Positive and Negative syndrome scale, Hamilton Depression Rating Scale, Hamilton Anxiety Scale, Clinical Global Impression, Scale for the Assessment of Negative Symptoms
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with akathisia according to DSM-IV criteria at least mild akathisia.
Exclusion Criteria:
- Change of pharmacologic regimen 7 days prior to study entry
- Significant systemic disease
- The presence of chronic akathisia
- Patients unable to cooperate
Locations and Contacts
Beer Yaakov MHC, Beer Yaacov 70350, Israel
Additional Information
Starting date: November 2000
Last updated: June 15, 2008
|
